TY - JOUR
AU1 - Benfield, Paul
AU2 - Heel, Rennie
AU3 - Lewis, Susan
AB - 
Synopsis: Fluoxetine1 is a new antidepressant which enhances serotoninergic neurotransmission through potent and selective inhibition of neuronal reuptake of serotonin. Metabolism by N-desmethylation occurs in man yielding desmethylfluoxetine, which also inhibits serotonin reuptake. Both the parent compound and metabolite possess elimination half-lives of several days facilitating the maintenance of steady-state plasma concentrations during long term treatment. Fluoxetine has overall therapeutic efficacy comparable with imipramine, amitriptyline and doxepin in patients with unipolar depression treated for 5 to 6 weeks, although it may be less effective than tricyclic antidepressants in relieving sleep disorders in depressed patients. Geriatric patients also responded as well to fluoxetine as to doxepin.
TI - Fluoxetine
JF - Drugs
DO - 10.2165/00003495-198632060-00002
DA - 2012-11-03
UR - https://www.deepdyve.com/lp/springer-journals/fluoxetine-Lmof5ZkhCJ
SP - 481
EP - 508
VL - 32
IS - 6
DP - DeepDyve
ER -